Parathyroidectomy and Cinacalcet Use in Medicare-Insured Kidney Transplant Recipients
Authors:
- Aileen X. WangAWAileen X. Wang
- Sai LiuSLSai Liu
- Maria E. Montez-RathMMMaria E. Montez-Rath
- Glenn M. ChertowGCGlenn M. Chertow
- Colin R. LenihanCLColin R. Lenihan
- 24 September 2022
- journal article
- research article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 81 (3) , 270-280.e1
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipientsSurgery, 2022
- US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United StatesAmerican Journal of Kidney Diseases, 2019
- Variable selection – A review and recommendations for the practicing statisticianBiometrical Journal, 2018
- KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)Kidney International Supplements, 2017
- Imputing missing covariate values for the Cox modelStatistics in Medicine, 2009
- Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving HemodialysisNew England Journal of Medicine, 2004
- Effect of waiting time on renal transplant outcomeKidney International, 2000
- Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric TransplantNew England Journal of Medicine, 1999
- Multiple imputation of missing blood pressure covariates in survival analysisStatistics in Medicine, 1999
- Calcimimetics with potent and selective activity on the parathyroid calcium receptorProceedings of the National Academy of Sciences, 1998